

# Instruction for SARS-CoV-2 Antigen Test Kit (Colloidal Gold)

## 1. Product Name

Generic name: SARS-CoV-2 Antigen Test Kit (Colloidal Gold)
Trade name: SARS-CoV-2 Antigen

## 2. Package

Subpackaged								
	REF							
Quantity	Nasopharyngeal Swab	Oropharyngeal Swab	Nasal Swab	Saliva Collector	Does not contain swabs and saliva collectors			
1T/kit	52104081	52104096	52104105	52104106	52104083			
5T/kit	52112079	52112085	52112096	52112097	52112080			
10T/kit	52025096	52025114	52025124	52025125	52025117			
20T/kit	52129002	52129003	52129012	52129013	52129006			
25T/kit	52026075	52026093	52026104	52026105	52026077			
50T/kit	52027077	52027092	52027102	52027103	52027095			
	Unpacked							

Unpacked								
	REF							
Quantity	Nasopharyngeal Swab	Oropharyngeal Swab	Nasal Swab	Saliva Collector	Does not contain swabs and saliva collectors			
5T/kit	52112088	52112089	52112090	52112091	52112092			
10T/kit	52025118	52025119	52025120	52025121	52025122			
20T/kit	52129007	52129008	52129009	52129010	52129011			
25T/kit	52026096	52026097	52026098	52026099	52026100			
50T/kit	52027096	52027097	52027098	52027099	52027100			

3. Intended Use & Indication
Genrui SARS-CoV-2 Antigen Test Kit (Colloidal Gold) is an immunochromatographic assay for rapid, qualitative detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen N protein from the nasel swab, nasopharynged swab, propharyngeal swab and saliva specimen. Suitable for all individuals suspect infected by SARS-CoV-2. The test is to be used as an aid in the diagnosis of coronavirus infectious disease (COVID-19), which is caused by SARS-CoV-2. The test provides preliminary results. Negative results cannot exclude SARS-CoV-2 infection and they cannot be used as the sole basis for treatment or other management decision.

For in vitro diagnostic use only. For professional use only.

## 4. Test Principle

4. Test Principle

This product uses highly specific antibody-antigen reaction and colloidal gold immunochromatographic technology. The reagent contains anti-SARS-CoV-2 monoclonal antibody pre-fixed on the test area (T) on the membrane and colloidal gold-conjugated anti-SARS-CoV-2 monoclonal antibody on the gold label pad.

During the test, the processed sample to be tested is dropped into the reagent loading place. When the sample contains SARS-CoV-2 antigen, the SARS-CoV-2 antigen in the sample is first combined with the anti-SARS-CoV-2 antibody labeled with colloidal gold, and then the conjugate is chromatographed upward under the conjugate is the colloidal gold, and then the conjugate is chromatographed upward. When the capillary effect, and it will be pre-immobilized on another membrane. When the anti-SARS-CoV-2 monoclonal antibody binds, a purple-red band will appear in the anti-SARS-COV-2 monocional antibody binds, a purple-red band will appear in the test area (T). If there is no SARS-COV-2 antigen in the sample, there will be no purple-red band in the test area (T). Regardless of whether the novel coronavirus antigen is present in the sample, a purple-red band will appear in the quality control area (C). The purple-red band in the quality control area (C) is the standard for judging whether there is enough sample and whether the chromatography process is normal, and it also serves as an internal control standard for reagents.

- (1) This kit is for in vitro diagnostic use only.

  (2) All specimens should be treated as capable of transmitting diseases. Use appropriate precaulitis in the collection, handling, storage and disposal of patient samples and used kit contents.
- (3) Wear appropriate personal protective equipment (e.g. protective gloves, medical (3) wear appropriate personal protective equipment (e.g. protective gloves, medical mask, goggles and lab coat) when handing the contents of this kit.
  (4) If the virus sampling solution is used for specimen processing, it can be directly detected without using extraction buffer.
  (5) Proper specimen collection, storage and transport are critical to the performance
- (6) Discard after first use. The sample extraction tube, the dropper and the test
- device cannot be reused.
  (7) Avoid high temperature during the experiment. Test cards and detection buffer stored at low temperature must be brought to room temperature before opening to avoid moisture absorption.
- (8) Do not touch the reaction area of test strip.(9) Do not use test kit beyond the expiration date.

- (10) Do not use the kit if the pouch is punctured or not well sealed.
  (11) Test should be performed by professionally trained staff working in certified laboratories or clinics at which the sample(s) is taken by qualified medical personnel.
  (12) The test result should be interpreted by the physician along with clinical findings and other laboratories are the contraction.
- (12) The test result should be interpreted by the physician along what clinical infallings and other laboratory test results.
  (13) Disposal of the diagnostic kits: All specimens and the used-kit have the infectious risk. For disposal of the diagnostic kits follow the local infectious disposal law or laboratory regulation.

# 6. Main Components& Additional required equipment

6. Main Components& Additional required equipment
The test kit consists of test card, sample diluent, extraction tube and the instruction.
(1) The test card consists of the card housing and test strip. Test strip contains a
sample pad, glass fiber (Colloidal gold labeled anti-SARS-CoV-2 monoclonal
antibody), nitrocellulose (NC) membrane, test area (T) is coated with
anti-SARS-CoV-2 monoclonal antibody, quality control area (C) is coated with goat
anti-mouse antibody, absorbent paper and PVC plate.
(2) Sample diluent: the main component is phosphate buffer (PBS).

7. Optional accessories: Nasopharyngeal swab, oropharyngeal swab, Nasal Swab,

saliva collector.									
Compon ent	Unpacked				Subpackaged				
Kit Size (# of Tests)	5	10	25	50	1	5	10	25	50
Test Card (#)	5	10	25	50	1	5	10	25	50
Sample Diluent	1× 8mL	1× 8mL	2× 8mL	4× 8mL	1× 0.5mL	5× 0.5mL	10× 0.5mL	25× 0.5mL	50× 0.5mL
Extraction Tube	5	10	25	50	1	1	1	1	1
Nasopharyn geal Swab	5	10	25	50	1	5	10	25	50
Oropharynge al Swab	5	10	25	50	1	5	10	25	50
Nasal Swab	5	10	25	50	1	5	10	25	50
Saliva Collector	5	10	25	50	1	5	10	25	50

# 8. Accessories Required But Not Provided (1) Viral Transport Media (VTM)

- (2) Tongue depressor (3) Extraction tube holder
- Timer
- (5) Personal protective equipment, such a protective gloves, medical mask, goggles and lab coat
- (6) Appropriate biohazard waste container and disinfectants.

(1) The test kit can be stored at 2-30 °C, aluminum foil bag in a sealed state is valid for 18 months, once opened, it is valid for 1 hour when the humidity is less than 65%. Make sure to use the product immediately after opening the packing bags when humidity is higher than 65%. Expiry of sample solution is 1 month from the date of opening. Production date is shown on the outer packing box.

(2) Transport at 2-30℃.

### 10.Sample Requirements

- (1) Nasal swab, oropharyngeal swab, nasopharyngeal swab and saliva can be used for testing.
- (2) The sample should be used as soon as possible after collection. If it cannot be used immediately, it must be stored at 2-8°C, use within 8 hours ,For long-term
- storage, it must be stored frozen below -70°C.

  (3) The samples must be equilibrated to room temperature (18-28°C) before testing. The frozen samples must be completely thawed, rewarmed, and mixed before use.

## 11.Specimen Collection and Preparation

The test can be performed with oropharyngeal swab, nasopharyngeal swab, nasal swab and saliva specimen.

- (1) According to standard specimen collection procedure.

  (2) Nasopharyngeal swab specimen collection: Tilt patient's head back to 70 degrees. Insert swab into nostril (Swab should reach a depth equal to the distance from nostrils to outer opening of the ear). Leave swab in place for several seconds to absorb secretions. Slowly remove swab while rotating it.

  (3) Oropharyngeal swab specimen collection: Insert swab into the posterior pharynx
- (a) Orbital yields awab speciment of collection. Insert swam into the posterior priary praying and tonsillar areas. Rub swab over both tonsillar pillars and posterior oropharynx and avoid touching the tongue, teeth, and gums.

  (4) Nasal swab collection: Insert the entire absorbent tip of the swab (usually 2cm) into left nostril. Firmly brush against insides of nostril in a circular motion 5 times or more for at least 15 seconds. Remove swab and insert it into right nostril. Firmly brush against insides of nostril in a circular motion 5 times or more for at least 15 seconds.
- (5) Saliva collection: 30 minutes before collecting saliva samples, please rinse the debris in your mouth with drinking water. After that, do not eat, drink, smoke or chew gum. Press the tongue on the base of the upper or lower jaw to enrich the saliva, and then gently spit the saliva into the collector.
  (6) It is recommended that the specimen is tested at the time of specimen collection. If
- the specimens are not tested immediately, they should be stored in a dry, disinfected tube and tightly sealed (Place tip of swab into a tube and snap/cut off the applicator stick). Samples may be stored at 2-8°C for up to 8 hours, or at -70°C for a longer period of time.

NOTE: If the viral transport medium (VTM) is needed for transporting samples, the dilution ratio for samples should be controlled at minimum level, since large diluent volume could result in false negative. If possible, the diluent volume should not exceed 1 mL (however, the tip of the swab must be immersed in the liquid). Taking influenza virus as a reference, the nasopharyngeal swab, oropharyngeal swab or nasal swab in the VTM can stay stable for up to 72 hours at 2-8°C. Recommend copan VTM.

## 12.Test Method

Carefully read the reagent instruction before using the test kit and strictly operate according to the instruction to ensure reliable results. Bring all reagents to room temperature (18-28°C) before use.


(1) Preparation

- a) Remove the test sample and required reagents from storage conditions and equilibrate to room temperature.
- b) Take out the test card from the packaging bag and lay it flat on a dry surface

(2). Sample processing

(1) For the unpacked type

For the unpacked type, insert the extraction tube vertically into the extraction tube holder, open the sample diluent bottle cap, and drop 0.5mL (about 10~12 drops) vertically into the extraction tube; For the pre-packed type, it can be used directly by opening the cap;



 $\ensuremath{@}$  Oropharyngeal swab , nasopharyngeal swab and nasal swab sample: Put the sample into the above diluent, rotate the swab against the tube wall 5-6 times, so that

Genrui Biotech Inc. Web: <u>www.genruibio.com</u> L00.2021032217-01



the swab will enter the sample diluent when the sample is completely released, let it stand for 1 minute, squeeze the tube wall, and take out the swab , Then cover the dripper and mix well, add 0.1mL (about  $3\sim4$  drops) of the evenly mixed solution in the extraction tube vertically to the sample hole of the test card; Read and interpret the test result at 15 minutes, the test result should not be read and interpreted after



## ③ Saliva:

Gently spit saliva into the collector until it reaches the position of line 1.



Close the bottle cap, shake and mix for 5-10 seconds or invert 7-8 times, add 0.1mL (about 3~ 4 drops) of the evenly mixed solution in the extraction tube vertically to the sample hole of the test card; Read and interpret the test result at 15 minutes, the test result should not be read and interpreted after 20 minutes.



④ The virus sampling solution is used for specimen processing, it can be directly

# detected without using sample diluent. 13.Explanation for Test Results



Positive Negative Invalid Invalid

- (1) Positive Result: The presence of control line (C) and the test line (T) indicate a positive result for the SARS-CoV-2 antigen.
- (2) Negative Result: The presence of only the control line (C) and no test line (T) indicates a negative result.
- (3) Invalid result: If the control line (C) is not visible after performing the test, the result is considered invalid. The sample needs to be tested again, indicating that the operation might be incorrect or the test card is deteriorated and damaged. In this case, please read the instruction carefully again and retest with a new test card. If the problem cannot be solved, you should stop using this batch of products immediately and contact the supplier.

# 14.Limitations

- (1) This test kit is for in vitro diagnostic use only and the results cannot be used as a basis for diagnosis. Comprehensive judgment should be made in combination with clinical symptoms, epidemiological conditions and further clinical data.
- (2) The accuracy of the test depends on the sample collection process. Improper sample collection, improper sample storage, or repeated freezing and thawing of the sample will affect the test result.

  (3) Positive test results do not rule out co-infections with other pathogens. A negative
- result of this reagent can be caused by:
  a) Improper sample collection, improper sample transfer or handing, the virus titer in the sample is too low.
  b) The level of SARS-CoV-2 antigen is below the detection limit of the test.
- c) Variations in viral genes may cause changes in determinants of the antibodies.
  d) Some special virus preservation solutions may not be applicable.
- (4) This product can only qualitatively detect the SARS-CoV-2 antigen in the sample and cannot determine the concentration of the antigen in the sample.
- (5) For medical professional use only. **15.Performance characteristic**

- (1) The limit of detection of this kit is 1.8x10<sup>2</sup> TCID<sub>50</sub>/mL.
- (2) Clinical performance:
- (2) Clinical perioritarities.

  a) Oropharyngeal swab, nasopharyngeal swab

  386 clinical case samples which include 181 confirmed as COVID-19 positive and

  205 confirmed as COVID-19 negative by RT-PCR assay, were obtained for testing,
  and then compared the test results of Genrui SARS-CoV-2 Antigen Test Kit (Colloidal

  Gold) with RT-PCR results. The results are shown below.

Gold) With IXI-1 CIX results. The results are shown below.					
	PCR	Subtotal			

	Pos	Neg		
SARS-CoV-2 Antigen	Pos	172	2	174
Test Kit (Colloidal Gold)	Neg	9	203	212
Subtotal		181	205	386

Positive Percent Agreement: 95.03% (95%CI: 90.77%~97.70%) Negative Percent Agreement: 99.02% (95%CI: 96.52%~99.88%) Overall Percent Agreement: 97.15% (95%CI: 94.96%~98.57%)

### b) Nasal swab

215 nasal swab samples which include 113 confirmed as COVID-19 positive and 102 confirmed as COVID-19 negative by RT-PCR assay, were obtained for testing, and then compared the test results of Genrui SARS-CoV-2 Antigen Test Kit (Colloidal Gold) with RT-PCR results. The results are shown below.

		PC	CR	Subtotal
		Pos	Neg	Subtotal
SARS-CoV-2 Antigen	Pos	103	1	104
Test Kit (Colloidal Gold)	Neg	10	101	111
Subtotal	113	102	215	

Positive Percent Agreement: 91.15% (95%CI: 84.33% 95.67%) Negative Percent Agreement: 99.02% (95%CI: 94.66%~99.98%) Overall Percent Agreement: 94.88% (95%CI: 91.03%~97.42%)

213 saliva samples which include 112 confirmed as COVID-19 positive and 101confirmed as COVID-19 negative by RT-PCR assay, were obtained for testing, and then compared the test results of Genrui SARS-CoV-2 Antigen Test Kit (Colloidal

Gold) With K1-FCK results. The results are shown below.						
	PC	Subtotal				
	Pos	Neg	Subtotal			
SARS-CoV-2 Antigen	Pos	101	1	102		
Test Kit (Colloidal Gold)	Neg	11	100	111		
Subtotal	112	101	213			

Positive Percent Agreement: 90.18% (95%CI: 83.11%~94.99%) Negative Percent Agreement: 99.01% (95%CI: 94.61%~99.98%) Overall Percent Agreement: 94.37% (95%CI: 90.37%~97.06%)

# 16.Internal quality control

Each test card has a built-in control. A red colored line at the control line can be considered an internal positive procedural control. The control line will appear if the procedure has been correctly performed. If the control line does not appear, the test is invalid and new test must be performed. If the problem persists, the use of this batch of products should be stopped immediately, please contact your local vendor for technical support.

17.Interfering substance
(1) Mucin≤10 g/L, blood≤10%, pus≤5% can·t interfere with the test results.
(2) Oxymetazoline≤0.375 mg/mL, Dexamethasone≤2.5 mg/L, Sulfur≤50 mg/mL, Zanamivir≤1.25 mg/L, Mupirocin≤5 mg/mL,Tobramycin≤0.8 mg/L can·t interfere with the test results

tion /mL n/mL
-
/mL
/mL
mL
mL
mL



Candida albicans	1.5 x 10 <sup>6</sup> CFU/mL
Bordetella pertussis	1.5 x 10 <sup>6</sup> CFU/mL
Mycoplasma pneumoniae	1.5 x 10 <sup>6</sup> CFU/mL
Chlamydia pneumoniae	1.5 x 10 <sup>6</sup> CFU/mL
Staphylococcus epidermidis	1.5 x 10 <sup>6</sup> CFU/mL
Staphylococcus aureus	1.5 x 10 <sup>6</sup> CFU/mL
Legionella pneumophila	1.5 x 10 <sup>6</sup> CFU/mL
Mycobacterium tuberculosis	1.5 x 10 <sup>6</sup> CFU/mL
Pneumocystis jirovecii (PJP)	1.5 x 10 <sup>6</sup> CFU/mL
Pooled human nasal wash	100%

Test kit has cross-reactivity with Human SARS-coronavirus nucleoprotein at a concentration of 25 ng/mL or more because SARS-CoV has high homology (79.6%) to the SARS-CoV-2.

## 18.Precautions

- (1) Once opened, use the test cards as soon as possible. Do not re-use the test

- cards.
  (2) Do not use expired products. Reagents should not be used if the product packaging bag is damaged or the sample diluent is leaking.
  (3) Do not interchange kit contents from different lots..
  (4) For substances containing sources of infection or suspected of containing sources of infection, there should be proper bio-safety assurance procedures. Pay attention to the following matters:
  a) Wear protective clothing, protection glasses and wear gloves when handling sample, operational process and disinfecting test cards and consumables after use.
  b) Disinfect spilled sample or reagent with disinfectant.
  c) Disinfect or handle potential contamination sources of all samples or reagents in accordance with local regulations.

- accordance with local regulations.
  d) Disposal of the device after use in accordance with local regulations.

# 19.Explanation of graphic symbol

□i	Consult Instructions for use	X	Temperature Limitation
LOT	Lot No.	X	Expiry Date
IVD	In Vitro Diagnostic Reagent	CE	CONFORMITE
IVU	III VIIIO Diagnostic Reagent	CE	EUROPEENNE
2	Production Date	4	Biohazard
<b>.</b>	Manufacturer	■	Volume
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Contains sufficient	756	Keep away
$\nabla$	for < n>tests		from sunlight
<b>(2)</b>	Do not re-use	<b>†</b>	Keep dry
	Authorized representative	DEE	Catalogue
EC REP	in the European community	REF	number

# 20.Help Information

If you need help please contact after-sales

## 21.Manufacturer

# Genrui Biotech Inc.

Address: 4-10F, Building 3, Geya Technology Park, Guangming District, 518106, Shenzhen, China.

Web: www.genrui-bio.com
E-mail: service@genrui-bio.com
Tel: +86 755 26835560 Fax: +86 755 26678789







Lotus NL B.V. Koningin Julianaplein 10, 1e Verd 2595AA, The Hague, Netherlands Email:peter@lotusnl.com